Use of additional domains and “other bias” | 100 Cochrane reviews (100 %) | 31 non-Cochrane reviews (100 %)c | P value* |
---|---|---|---|
Additional domains | |||
Any additional domain(s) | 11 (11 %) | 6 (19 %) | 0.37 |
-Adds “baseline imbalance” | 6 of 11 (55 %) | 2 of 6 (33 %) | 1.00 |
-Adds “funding” or “conflicts of interest” | 5 of 11 (45 %) | 1 of 6 (17 %) | 0.62 |
-Adds “intention to treat” | 2 of 11 (18 %) | 2 of 6 (33 %) | 0.62 |
-Adds “compliance” | 2 of 11 (18 %) | 1 of 6 (17 %) | 1.00 |
-Adds “follow up” | 3 of 11 (27 %) | 2 of 6 (33 %) | 1.00 |
-Adds “timing of outcome assessment” | 2 of 11 (18 %) | 1 of 6 (17 %) | 1.00 |
-Adds “overall risk of bias” | 1 of 11 (9 %) | 4 of 6 (67 %) | 0.14 |
-Adds other additional domaina | 6 of 11 (55 %) | 2 of 6 (33 %) | 1.00 |
Other biasb | |||
Includes the “other bias” domain | 73 (73 %) | 17 (55 %) | 0.41 |
-Used for “baseline imbalance” | 33 of 73 (45 %) | 0 of 17 (0 %) | 0.0059 |
-Used for “funding” or “conflicts of interest” | 23 of 73 (32 %) | 2 of 17 (12 %) | 0.24 |
-Used for “intervention differed between groups” | 16 of 73 (22 %) | 0 of 17 (0 %) | 0.069 |
-Used for “unclear reporting by trial publication author” | 15 of 73 (21 %) | 0 of 17 (0 %) | 0.12 |
-Used for “trial design” | 11 of 73 (15 %) | 0 of 17 (0 %) | 0.20 |